Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05746481 | Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | terminated | Phase 2 | 3 | Liza Villaruz, MDOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06322576 | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma | terminated | Phase 2 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | terminated | Phase 1 / Phase 2 | 5 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | terminated | Phase 2 | 1 | Anwaar SaeedOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy(STIMULUS-AML1) | terminated | Phase 2 | 90 | Novartis PharmaceuticalsINDUSTRY | 10 | Jan 13, 2026 | clinicaltrials |
| NCT04379518 | Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 146 | Novartis PharmaceuticalsINDUSTRY | 14 | Jan 13, 2026 | clinicaltrials |
| NCT03870750 | Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases | terminated | Phase 2 / Phase 3 | 458 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy(neoMono) | terminated | Phase 2 | 442 | Palleos Healthcare GmbHINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04585815 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | terminated | Phase 1 / Phase 2 | 34 | PfizerINDUSTRY | 4 | Jan 9, 2026 | clinicaltrials |
| NCT05799079 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | terminated | Phase 2 | 1 | Sanjay MohanOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | terminated | Phase 2 | 19 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | terminated | Phase 2 | 54 | ExelixisINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04966676 | Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer(ATLAS) | terminated | Phase 2 | 5 | University Health Network, TorontoOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04163718 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy(ELPIS) | terminated | Phase 2 | 5 | Fundacio Clinic BarcelonaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04240002 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 9 | Astellas Pharma Global Development, Inc.INDUSTRY | 5 | Jan 5, 2026 | clinicaltrials |
| NCT04425070 | A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma(TOUCH) | terminated | Phase 1 / Phase 2 | 56 | Antengene CorporationINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | terminated | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03708003 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | terminated | Phase 2 | 30 | Swiss Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | terminated | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations(FIGHT-209) | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 9 | Dec 30, 2025 | clinicaltrials |
| NCT06106841 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | terminated | Phase 1 / Phase 2 | 19 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT03055286 | Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | terminated | Phase 1 / Phase 2 | 15 | JW PharmaceuticalINDUSTRY | 2 | Dec 26, 2025 | clinicaltrials |
| NCT05141357 | A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer(HBI-8000) | terminated | Phase 2 | 5 | HUYABIO International, LLC.INDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | terminated | Phase 2 | 24 | University of ChicagoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06359379 | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter | terminated | Phase 2 | 30 | Shuttle Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma(CARTIFAN-1) | terminated | Phase 2 | 123 | Nanjing Legend Biotech Co.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04688658 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 13 | John KirkwoodOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.(HN1901) | terminated | Phase 2 | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04765709 | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC(BRIDGE) | terminated | Phase 2 | 10 | Mario Negri Institute for Pharmacological ResearchOTHER | 3 | Dec 16, 2025 | clinicaltrials |
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | terminated | Phase 1 / Phase 2 | 5 | Medical University of South CarolinaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06818305 | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT(EmFin-Nx) | terminated | Phase 2 | 10 | Jinling Hospital, ChinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer(TrasTUCAN) | terminated | Phase 2 | 13 | Spanish Breast Cancer Research GroupOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT01570868 | Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) | terminated | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03595683 | Pembrolizumab and EDP1503 in Advanced Melanoma | terminated | Phase 2 | 8 | University of ChicagoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | terminated | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05918055 | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05464836 | Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 22, 2026source: clinicaltrials